If I Were a VP or a VC…
View Presentation *Cong Chen, Merck Research Laboratories Keywords: How would I invest if I were a vice president (VP) in charge of a drug portfolio or a venture capitalist interested in biopharmaceutical industry? In this presentation, I will address a variety of questions frequently encountered in late-stage drug development via explicit optimization of the return/investment ratio. They include: 1) how to set cost-effective Go-No Go criteria for Phase II proof-of-concept (POC) trials; 2) how to re-distribute resource when there are more POC opportunities than can afford; 3) how to deal with a possible response subpopulation; 4) how to set a cost-effective futility bar in subsequent Phase III trials; 5) what is the optimal program level strategy. The same assumptions as used in an otherwise qualitative and subjective decision process, but nothing else, will be adopted in the proposed objective decision analysis.
|
Key Dates
-
April 30 - May 22, 2013
Invited Abstract Submission Open -
June 4, 2013
Online Registration Opens -
August 9 - August 23, 2013
Invited Abstract Editing -
August 23, 2013
Short Course materials due from Instructors -
August 26, 2013
Housing Deadline -
September 9, 2013
Cancellation Deadline and Registration Closes @ 11:59 pm EDT -
September 16 - September 18, 2013
Marriott Wardman Park, Washington, DC